EGFR and non-small cell lung carcinoma: Another phase-I clinical trial (NCT01869166) of EGFR CAR-T cell therapy in 11 patients with EGFR+ refractory/relapsed non-small cell lung cancer (NSCLC) demonstrated that 2 patients achieved a partial response, and 5 had stable disease for 2 to 8 months without severe toxicity (39).